This is a summary of the European public assessment report (EPAR) for Levetiracetam Sun. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Sun.
Therapeutic Indication
### Therapeutic indication Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Levetiracetam Sun is indicated as adjunctive therapy: - in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy; - in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; - in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy. Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.
Therapeutic Area (MeSH)
ATC Code
N03AX14
ATC Item
levetiracetam
Pharmacotherapeutic Group
Other antiepileptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| levetiracetam | N/A | 左乙拉西坦 |
EMA Name
Levetiracetam Sun
Medicine Name
Levetiracetam Sun
Aliases
N/ANo risk management plan link.
